Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer

By sjmartinez • November 3, 2023

Zelba H, Rabsteyn A, Bartsch O, Kyzirakos C, Kayser S, Seibold M, Harter J, Latzer P, Hadaschik D, Battke F, Golf A, Rettig MB, Biskup S. Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer. Front Immunol. 2023 Oct 18;14:1271449. doi: 10.3389/fimmu.2023.1271449. PMID: 37920460; PMCID: PMC10619716.

Tags: APC, Cardiology/Epi, Harbor UCLA, neoantigen, peptide, prostate cancer, Publications, Vaccination

Related Posts

The Cardiovascular Care of the Pediatric Athlete

Dean PN, Brothers JA, Burns K, Edelson JB, Etheridge S, Phelan DM, Shafer K, Snyder C, Molossi S, Danielian A, Friedman EM, Hsu J, Husaini[...]

Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study

Freaney PM, Huang X, Petito LC, Grobman WA, Catov J, Hauspurg A, Bairey Merz CN, Bello N, Kim JK, Lane A, Haas DM, Levine LD,[...]

Prototyping and Manufacturing of Customized Over-Encapsulated Polypills for Heart Failure with Reduced Ejection Fraction in a Safety-Net Healthcare System

DeJong C, Durstenfeld MS, Davis J, Wang CS, Chen J, Kazi DS, Hickey MD, Grochowski J, Steward WT, Riley ED, Zier LS, Moreau N, Huffman[...]